Relay Therapeutics Inc
RLAY
View Detailed Chart
8.920USD
+0.770+9.45%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.54BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+9.45%
5 Days
+16.45%
1 Month
+9.18%
6 Months
+152.69%
Year to Date
+5.44%
1 Year
+97.78%
View Detailed Chart
TradingKey Stock Score of Relay Therapeutics Inc
Currency: USD Updated: 2026-02-06Key Insights
Relay Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 13 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 14.55.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Relay Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Relay Therapeutics Inc Highlights
StrengthsRisks
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 624.62% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 10.01M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 10.01M.
Undervalued
The company’s latest PE is -5.20, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 170.34M shares, decreasing 20.08% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 285.09K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.27.
Analyst Rating
Based on
12
analysts
Strong Buy
Current Rating
14.545
Target Price
+78.47%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Relay Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Relay Therapeutics Inc Info
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
Ticker SymbolRLAY
CompanyRelay Therapeutics Inc
CEOPatel (Sanjiv K)
Websitehttps://relaytx.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69060.000
-910.130 (-1.30%)
282.580
+22.390 (+8.61%)
2056.490
+4.760 (+0.23%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
